Clinical Trials Logo

Filter by:
NCT ID: NCT04410692 Completed - Clinical trials for Health Knowledge, Attitudes, Practice

Can the Prediction Market Improve Predictions of COVID-19?

Start date: May 15, 2020
Phase: N/A
Study type: Interventional

The goal of this study is to better understand how people predict the future risks of the novel Coronavirus (COVID-19). Specifically, the investigators will ask the following research questions: - How well do participants predict the future risks of COVID-19? - Can the predictions be improved by using a prediction market mechanism? - Does the prediction market reduce people's fear of COVID-19?

NCT ID: NCT04401579 Completed - COVID-19 Clinical Trials

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

Start date: May 8, 2020
Phase: Phase 3
Study type: Interventional

ACTT-2 will evaluate the combination of baricitinib and remdesivir compared to remdesivir alone. Subjects will be assessed daily while hospitalized. If the subjects are discharged from the hospital, they will have a study visit at Days 15, 22, and 29. For discharged subjects, it is preferred that the Day 15 and 29 visits are in person to obtain safety laboratory tests and oropharyngeal (OP) swab and blood (serum only) samples for secondary research as well as clinical outcome data. However, infection control or other restrictions may limit the ability of the subject to return to the clinic. In this case, these visits may be conducted by phone, and only clinical data will be obtained. The Day 22 visit does not have laboratory tests or collection of samples and is conducted by phone. The primary outcome is time to recovery by Day 29.

NCT ID: NCT04400929 Completed - COVID Clinical Trials

Using GM-CSF as a Host Directed Therapeutic Against COVID-19

Start date: June 2, 2020
Phase: Phase 2
Study type: Interventional

The coronavirus disease 2019 (COVID-19) has rapidly become a pandemic. COVID-19 poses a mortality risk of 3-7%, rising to 20% in older patients with co-morbidities. Of all infected patients, 15-20% will develop severe respiratory symptoms necessitating hospital admission. Around 5% of patients will require invasive mechanical ventilation, and up to 50% will die. Evidence in severe COVID-19 suggests that these patients experience cytokine storm and progressed rapidly with acute respiratory distress syndrome and eventual multi-organ failure. Early identification and immediate treatment of hyperinflammation is thus recommended to reduce mortality. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) has been shown to be a myelopoietic growth factor that has pleiotropic effects in promoting the differentiation of immature precursors into polymorphonuclear neutrophils, monocytes/ macrophages and dendritic cells, and also in controlling the function of fully mature myeloid cells. It plays an important role in priming monocytes for production of proinflammatory cytokines under TLR and NLR stimulation. It has a broad impact on the processes driving DC differentiation and affects DC effector function at the mature state. Importantly, GM-CSF plays a critical role in host defense and stimulating antiviral immunity. Detailed studies have also shown that GM-CSF is necessary for the maturation of alveolar macrophages from foetal monocytes and the maintenance of these cells in adulthood. The known toxicology, pharmacologic and safety data also support the use of Leukine® in hypoxic respiratory failure and ARDS due to COVID-19. This study aims to recruit patients with evidence of pneumonia and hypoxia who have increased risk for severe disease and need for mechanical ventilation. The overall hypothesis is that GM-CSF has antiviral immunity, can provide the stimulus to restore immune homeostasis in the lung with acute lung injury from COVID-19, and can promote lung repair mechanisms, which would lead to improvement in lung oxygenation parameters.

NCT ID: NCT04395781 Completed - COVID Clinical Trials

Pediatric Acute and Critical Care COVID-19 Registry of Asia

PACCOVRA
Start date: May 18, 2020
Phase:
Study type: Observational [Patient Registry]

In December 2019, an outbreak of pneumonia of unknown aetiology was first reported in the city of Wuhan, Hubei Province, People's Republic of China. Since then, a novel coronavirus, 2019 novel Coronavirus (2019-nCoV) has emerged as the most likely causative agent. To date, it has evolved into a pandemic involving over a million cases and thousands of deaths have been identified, including a high burden in countries like Italy, Spain, United Kingdom and the United States. This study aims to investigate the clinical epidemiology of 2019-novel coronavirus (2019-nCoV) pandemic in Asia.

NCT ID: NCT04395430 Completed - Pediatric Obesity Clinical Trials

A Novel School-clinic-community Online Model of Child Obesity Treatment in Singapore During COVID-19

Start date: September 18, 2020
Phase: N/A
Study type: Interventional

Background: The Coronavirus 2019 (COVID-19) is an infectious disease, which was first identified in December 2019 and has then spread rapidly around the world. COVID-19 spreads mainly through respiratory droplets and causes people to experience mild to moderate respiratory illness. On 11 March 2020, the World Health Organisation (WHO) declared COVID-19 a pandemic. With the surge in cases and to contain the spread of this disease, Singapore implemented a circuit breaker to reduce movements and interactions in public and private places. People are advised to stay at home and practise social distancing. With restrictions in movements, parents and children are likely to be more sedentary in this pandemic. There is an urgent need to move face-to-face interventions to online interventions as it is important to be active in this period. Childhood obesity threatens the health of US and Singapore populations. In the US, 30% of children are overweight, 17% have obesity, and 8% have severe obesity. In Singapore, 13% of children have obesity, and approximately half of all overweight children live in Asia. In both countries the prevalence is increasing, especially amongst the lower income populations, and is associated with future cardiovascular and metabolic disease. In US, obesity is most prevalent in Black and Hispanic populations and in Singapore, obesity affects Malays and Indians disproportionately. The underlying drivers and potential solutions thus share many common factors. The current evidence shows a clear dose-response effect with increasing number of hours of treatment, with a threshold for effectiveness at > 25 hours over a 6-month period. A key gap in delivering this recommendation is meeting the intensity, and delivering comprehensive treatment that is culturally relevant, engaging to families, and integrated within the community context. The study is an online pilot randomised controlled trial among children aged 4-7 with obesity, in Singapore, to test a novel school-clinic-community online intervention, the KK Hospital (KKH) Sports Singapore program, for child obesity treatment with usual care. The primary outcome is intensity of treatment as measured by hours of exposure to intervention. The online KKH Sports Singapore program involves 4-6 weekly online sessions of physical activity and nutrition lessons for children and parents.

NCT ID: NCT04394039 Completed - Anxiety Clinical Trials

Post-Pandemic Perception of Public Space in Singapore

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

In this study it is aimed to investigate the difference between the brain response to different urban environments in Singapore before and after the COVID-19 pandemic. The datasets acquired from 34 healthy individuals as part of ongoing study "Effects of Landscape on the Brain" (IRB Ref #: S-18-352) will be used. These datasets consist of neurophysiological data recordings and behavioral self-reported measures and were collected before 20 of January 2020. The same experimental protocol would be followed, given that the data collection in the lab-setting would start after 7 th May 2020/whenever research activities are allowed to resume, and the outdoor sessions after the "circuit-breaker" period in Singapore is over.

NCT ID: NCT04385368 Completed - Clinical trials for Carcinoma, Non-Small-Cell Lung

Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

MERMAID-1
Start date: July 17, 2020
Phase: Phase 3
Study type: Interventional

This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery

NCT ID: NCT04385147 Completed - COVID-19 Clinical Trials

Advanced Endoscopy During COVID-19

Start date: May 18, 2020
Phase:
Study type: Observational

In this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.

NCT ID: NCT04368091 Completed - Atherosclerosis Clinical Trials

Clinical Use and Safety of the Xtreme Touch (Magic Touch PTA)- Neo Sirolimus Coated PTA Balloon Catheter in the Treatment of Infrainguinal Peripheral Arterial Disease

XTOSI
Start date: November 21, 2018
Phase:
Study type: Observational

This study postulates that the application of Sirolimus, an anti-proliferative agent that inhibits neointimal hyperplasia, via Sirolimus coated balloon (SCB) will be safe and will result in better arterial patency in infrainguinal peripheral arterial disease (PAD). The aim is to evaluate the efficacy (12 month freedom from clinically driven target lesion revascularisation) and safety (freedom from major adverse events) of sirolimus coated balloons in the treatment of infrainguinal PAD.

NCT ID: NCT04367363 Completed - Depression Clinical Trials

Social Media and COVID-19

Start date: March 17, 2020
Phase:
Study type: Observational

In this protocol, we seek to examine the role of popular messaging platform WhatsApp in information spread during a crisis. As there have been few global crises in the last decade (coinciding with the rise of social media), the role of private messaging platforms such as WhatsApp during crisis contexts remains understudied. During the current COVID-19 global health crisis, we undertook this study to: (1) characterize the nature of WhatsApp use during crises, (2) characterize the profiles of WhatsApp users (3) understand how WhatsApp usage links to well-being (fear and thoughts about COVID-19).